Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC) Meeting Abstract
| Authors: | Krop, I.; Yonemori, K.; Takahashi, S.; Inoue, K.; Nakayama, T.; Iwata, H.; Toyama, T.; Yamamoto, Y.; Takahashi, M.; Osaki, A.; Saji, S.; Sagara, Y.; O'Shaughnessy, J.; Traina, T.; Ohwada, S.; Qi, Z.; Qiu, Y.; Onuma, H.; Sharma, O.; Mekan, S.; Masuda, N. |
| Abstract Title: | Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC) |
| Meeting Title: | 43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Dec 8-11 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-02-01 |
| Language: | English |
| ACCESSION: | WOS:000618737700131 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS20-PD1-09 |
| Notes: | Meeting Abstract: PD1-09 -- This symposium was held virtually due to COVID-19 -- Source: Wos |
